Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment
A partir des données de deux cohortes ("St Jude Lifetime Study" et "St Jude Long-term Follow-up Study") incluant 348 patients ayant survécu plus de 10 ans à un lymphome hodgkinien pendant l'enfance et ayant atteint l'âge de 18 ans ou plus, ainsi que 272 témoins, cette étude évalue l'incidence et la prévalence des morbidités cardiovasculaires
Children, teenagers, and young adults diagnosed with Hodgkin's lymphoma a decade ago had an excellent prognosis, with 10-year overall survival above 90%.1 For those diagnosed today, outcomes should be even better through efforts to prevent side-effects by reducing treatment as far as possible without compromising cure. In The Lancet Oncology, a report by Nickhill Bhakta and colleagues2 from the St Jude Lifetime Cohort Study (SJLIFE) shows that, in 10-year survivors of Hodgkin's lymphoma diagnosed between 1961 and 2004 who reached at least 18 years of age, treatment-related cardiovascular morbidity ranged from subclinical to life-threatening, with new manifestations continuing to appear during several decades of follow-up.
The Lancet Oncology , commentaire, 2015